Production of fatty acids esters

Abstract

A microbial cell is used for producing at least one fatty acid ester, wherein the cell is genetically modified to contain (i) at least one first genetic mutation that enables the cell to produce at least one fatty acid and/or acyl coenzyme A (CoA) thereof by increased enzymatic activity in the cell relative to the wild type cell of malonyl-CoA dependent and malonyl-ACP independent fatty acyl-CoA metabolic pathway, wherein the fatty acid contains at least 5 carbon atoms; and (ii) a second genetic mutation that increases the activity of at least one wax ester synthase in the cell relative to the wild type cell and the wax ester synthase has sequence identity of at least 50% to a polypeptide of SEQ ID NO: 1-8 and combinations thereof or to a functional fragment of any of the polypeptides for catalyzing the conversion of fatty acid and/or acyl coenzyme A thereof to the fatty acid ester.

Claims

1. A microbial cell for producing at least one fatty acid ester, wherein the cell comprises: (i) a first genetic mutation that enables the cell to produce at least one fatty acyl coenzyme A (CoA) intermediate by an increase in the expression of at least one enzyme selected from the group consisting of acetoacetyl-CoA synthase, ketoacyl-CoA synthase (or elongase), ketoacyl-CoA thiolase, enoyl-CoA reductase, ketoacyl-CoA reductase and 3-hydroxyacyl-CoA dehydratase relative to a wild type cell; and (ii) a second genetic mutation that increases the activity of at least one wax ester synthase in the cell relative to the wild type cell, wherein the wax ester synthase has sequence identity of at least 80% to a polypeptide set forth in SEQ ID NO: 1, at least 80% to a polypeptide set forth in SEQ ID NO: 2, at least 85% to a polypeptide as set forth in SEQ ID NO: 3, at least 85% to a polypeptide as set forth in SEQ ID NO: 4, at least 90% to a polypeptide as set forth in SEQ ID NO: 5, at least 95% to a polypeptide as set forth in SEQ ID NO: 7, or at least 98% to a polypeptide as set forth in SEQ ID NO: 8, and combinations thereof or to a functional fragment of any of the polypeptides for catalyzing the conversion of the fatty acyl coenzyme A intermediate to a fatty acid ester.

2. The cell according to claim 1, wherein the at least one fatty acyl coenzyme A (CoA) intermediate comprises a C4 to C10 acyl-CoA substrate.

3. The cell according to claim 1, further comprising a genetic mutation that results in a decrease in the expression of acetoacetyl-CoA thiolase relative to the wild type cell.

4. The cell according to claim 1, wherein the cell comprises a third genetic mutation that reduces the fatty acid degradation capacity of the cell relative to the wild type cell.

5. The cell according to claim 4, wherein the third genetic mutation results in a decrease in the expression of at least one enzyme selected from the group consisting of acyl-CoA dehydrogenase, 2,4-dienoyl-CoA reductase, enoyl-CoA hydratase and 3-ketoacyl-CoA thiolase, each relative to the wild type cell.

6. The cell according to claim 1, wherein the cell is genetically modified to increase the expression of -ketoacyl-ACP synthase III (fabH) relative to the wild type cell.

7. The cell according to claim 6, wherein the -ketoacyl-ACP synthase III (fabH) has sequence identity of at least 85% to a polypeptide selected from the group consisting of SEQ ID NOs: 24-27 and combinations thereof.

8. The cell according to claim 1, wherein the cell is genetically modified to increase the expression of 3-hydroxyacyl coenzyme A dehydratase (3HCDh) and/or keto acyl-CoA reductase (KCR) relative to the wild type cell.

9. The cell according to claim 8, wherein the 3HCDh is crotonase/enoyl-CoA hydratase (Crt) and the KCR is hydroxybutyric dehydrogenase (Hbd).

10. The cell according to claim 9, wherein the Crt has sequence identity of at least 85% to a polypeptide as set forth in SEQ ID NO:28 and/or the Hbd has sequence identity of at least 85% to a polypeptide of SEQ ID NO:29.

11. The cell according to claim 1, wherein the fatty acid ester is a fatty acid methyl ester (FAME) and/or a fatty acid ethyl ester (FAEE).

12. The cell according to claim 1, wherein the fatty acid ester is produced in the presence of at least one exogenous alcohol selected from the group consisting of methanol, ethanol, propanol, butanol, and pentanol.

13. The cell according to claim 1, wherein the cell is a yeast cell, a fungi cell, or a bacteria cell.

14. The cell according to claim 13, wherein the cell is a selected from the group consisting of Pseudomonas putida, Escherichia coli, and Saccharomyces cerevisiae.

15. A method for producing fatty acid ester, the method comprising: contacting at least one fatty acyl coenzyme A (CoA) intermediate with an isolated wax ester synthase that has sequence identity of at least 80% to a polypeptide set forth in SEQ ID NO: 1, at least 85% to a polypeptide as set forth in SEQ ID NO: 3, at least 85% to a polypeptide as set forth in SEQ ID NO: 4, at least 90% to a polypeptide as set forth in SEQ ID NO: 5, at least 95% to a polypeptide as set forth in SEQ ID NO: 7, or at least 98% to a polypeptide as set forth in SEQ ID NO: 8.

16. A method for producing at least one fatty acid ester, the method comprising culturing a microbial cell which comprises: (i) a first genetic mutation that enables the cell to produce at least one fatty acyl coenzyme A (CoA) intermediate by an increase in the expression of at least one enzyme selected from the group consisting of acetoacetyl-CoA synthase, ketoacyl-CoA synthase (or elongase), ketoacyl-CoA thiolase, enoyl-CoA reductase, ketoacyl-CoA reductase and 3-hydroxyacyl-CoA dehydratase relative to a wild type cell; and (ii) a second genetic mutation that increases the activity of at least one wax ester synthase in the cell relative to the wild type cell, wherein the wax ester synthase has sequence identity of at least 80% to a polypeptide set forth in SEQ ID NO: 1, at least 80% to a polypeptide set forth in SEQ ID NO: 2, at least 85% to a polypeptide as set forth in SEQ ID NO: 3, at least 85% to a polypeptide as set forth in SEQ ID NO: 4, at least 90% to a polypeptide as set forth in SEQ ID NO: 5, at least 95% to a polypeptide as set forth in SEQ ID NO: 7, or at least 98% to a polypeptide as set forth in SEQ ID NO: 8, and combinations thereof or to a functional fragment of any of the polypeptides for catalyzing the conversion of the fatty acyl coenzyme A intermediate to a fatty acid ester.

17. The cell according to claim 16, wherein the fatty acid ester is a fatty acid methyl ester (FAME) and/or a fatty acid ethyl ester (FAEE).

18. The cell according to claim 16, wherein the fatty acid ester is produced in the presence of at least one exogenous alcohol selected from the group consisting of methanol, ethanol, propanol, butanol, and pentanol.

Description

BRIEF DESCRIPTION OF DRAWINGS

(1) FIG. 1 is a graph showing free fatty acid (FFA) production in shake flask cultures after 68 hours for four FFA production strains.

(2) FIG. 2 is a graph showing the lauric acid production profile for BXF_169 evaluated in 50 ml shake flask, OD.sub.600=2.

(3) FIG. 3 is a graph showing the mRNA expression relative to cysG for various pathway genes in BXF_169 measured at 8, 24 and 48 hrs.

(4) FIG. 4 is a graph showing the enzyme activity for various elongation steps measured in lysate for BXF_169 at 8 and 24 hours. EnCR activity is encoded by the Ter gene. KAS activities are encoded by the NphT7 and FabH genes.

(5) FIG. 5 is a graph showing intermediate product formation and utilization specific to the C4.fwdarw.C6 elongation steps of the lauroyl-CoA production pathway (data collected but not shown for the C6.fwdarw.C12 intermediates) from in vitro pathway reconstitution with FadB, FadB+Crt and FadB+Crt+Hbd.

(6) FIG. 6 is a graph showing product formation measured for 20 soluble WES candidates. Purified candidate enzymes were incubated individually with methanol and C6- to C14-CoA substrates to assess product formation.

(7) FIG. 7 is a graph showing FAME production at 24 hours for nine thiolase-based strains expressing different wax ester synthase candidates evaluated with the 2 mL small-scale protocol.

(8) FIG. 8 is a graph showing the production of methyl laurate and other FAMEs (C6-C14) in 1 ml, 24 hour strain screening assay by 50 strains engineered with various versions of the synthase pathway for methyl laurate production.

(9) FIG. 9 is a graph showing FAME product distribution exhibited by strain BXE_022 after 40 hrs in 1 L fermentation under various test conditions.

(10) FIG. 10 is a graph showing FAME and FFA concentration distribution for strains BXE_058 and BXE_062 at approximately 45 hours of production; methyl myristate concentration was not include in the analysis as 50 g/L was added as a second phase.

(11) FIG. 11 is an illustration of the metabolic pathways of a cell related to genetic modifications for increasing flux through the intermediate malonyl-CoA

(12) FIG. 12 is a graph showing the evaluation of intermediate product accumulation specific to the C4.fwdarw.C6 elongation steps of the lauroyl-CoA production pathway (data collected but not shown for the C6.fwdarw.C12 intermediates.)

(13) FIG. 13 is a graph showing specific enzyme activities for three FabH mutant enzymes with C6-C10-CoA substrates compared to wild-type FabH.

(14) FIG. 14 is a graph showing FAME production in standard 1 mL method after 20 hours of production. (Note: BXE_198 is the control comparison for BXE_271-273 and BXE_233 is the control for BXE_243-244).

(15) FIG. 15 is a graph showing FAME production in standard 1 mL method after 20 hours of production with alternative WES enzyme candidates.

(16) FIG. 16 is a graph showing in vitro product formation from methanol and C12-CoA after incubation for 5 minutes with purified Mhyd variants as measured by GC-MS.

(17) FIG. 17 is a graph showing FAME production in standard 1 mL method after 20 hours of production with Maqu mutants (SEQ ID NOs:7 and 8).

(18) FIG. 18 is a graph showing WES enzyme activities for BXE_062 and BXE_233 cell lysates as measured by product formation over time by GC-MS. The target activity for WES in cell lysates is 0.02 U/mg.

(19) FIG. 19 is a graph showing average production profile for methyl laurate and total FAME for 1 L fermentations with BXE_276 in the FM14 process.

DETAILED DESCRIPTION OF THE INVENTION

(20) The ranges described below include all values and subvalues between the lower and upper limit of the range.

(21) According to one aspect, the present invention provides a microbial cell for producing at least one fatty acid ester, wherein the cell is genetically modified to comprise: at least one first genetic mutation that enables the cell to produce at least one fatty acid and/or acyl coenzyme A thereof, wherein the fatty acid comprises at least 5 carbon atoms; and at least one second genetic mutation that increases the activity of at least one wax ester synthase in the cell relative to the wild type cell and the wax ester synthase has sequence identity of at least 50% to a polypeptide of SEQ ID NOs: 1-8 and combinations thereof or to a functional fragment of any of the polypeptides for catalyzing the conversion of fatty acid and/or acyl coenzyme A thereof to the fatty acid ester.

(22) In particular, the cell may be capable of producing the fatty acid and/or acyl coenzyme A thereof by means of increased enzymatic activity in the cell relative to the wild type cell of the malonyl-CoA dependent and malonyl-ACP independent fatty acyl-CoA metabolic pathway.

(23) The microbial cells according to any aspect of the present invention may be prokaryotes or eukaryotes. These can be mammalian cells (such as, for example, cells from man), plant cells or microorganisms such as yeasts, fungi or bacteria, wherein microorganisms in particular bacteria and yeasts may be used.

(24) Suitable bacteria, yeasts or fungi are in particular those bacteria, yeasts or fungi that are deposited in the Deutsche Sammlung von Mikroorganismen and Zellkulturen (German Collection of Microorganisms and Cell Cultures) GmbH (DSMZ), Brunswick, Germany, as bacterial, yeast or fungal strains. Bacteria suitable according to the invention belong to the genera that are listed in the Deutsche Sammlung von Mikroorganismen and Zellkulturen (German Collection of Microorganisms and Cell Cultures) GmbH(DSMZ) Germany.

(25) Yeasts suitable according to the invention belong to the genera that are listed in the Deutsche Sammlung von Mikroorganismen and Zellkulturen (German Collection of Microorganisms and Cell Cultures) GmbH (DSMZ), Brunswick, Germany.

(26) Fungi suitable according to the invention belong to the genera that are listed in the Deutsche Sammlung von Mikroorganismen and Zellkulturen (German Collection of Microorganisms and Cell Cultures) GmbH (DSMZ), Brunswick, Germany.

(27) In particular, the cells may be selected from the genera Aspergillus, Corynebacterium, Brevibacterium, Bacillus, Acinetobacter, Alcaligenes, Lactobacillus, Paracoccus, Lactococcus, Candida, Pichia, Hansenula, Kluyveromyces, Saccharomyces, Escherichia, Zymomonas, Yarrowia, Methylobacterium, Ralstonia, Pseudomonas, Rhodospirillum, Rhodobacter, Burkholderia, Clostridium and Cupriavidus. More in particular, the cells may be selected from the group consisting of Aspergillus nidulans, Aspergillus niger, Alcaligenes latus, Bacillus megaterium, Bacillus subtilis, Brevibacterium flavum, Brevibacterium lactofermentum, Burkholderia andropogonis, B. brasilensis, B. caledonica, B. caribensis, B. caryophylli, B. fungorum, B. gladioli, B. glathei, B. glumae, B. graminis, B. hospita, B. kururiensis, B. phenazinium, B. phymatum, B. phytofirmans, B. plantarii, B. sacchari, B. singaporensis, B. sordidicola, B. terricola, B. tropica, B. tuberum, B. ubonensis, B. unamae, B. xenovorans, B. anthina, B. pyrrocinia, B. thailandensis, Candida blankii, Candida rugosa, Corynebacterium glutamicum, Corynebacterium efficiens, Escherichia coli, Hansenula polymorpha, Kluveromyces lactis, Methylobacterium extorquens, Paracoccus versutus, Pseudomonas argentinensis, P. borbori, P. citronellolis, P. flavescens, P. mendocina, P. nitroreducens, P. oleovorans, P. pseudoalcaligenes, P. resinovorans, P. straminea, P. aurantiaca, P. aureofaciens, P. chlororaphis, P. fragi, P. lundensis, P. taetrolens, P. antarctica, P. azotoformans, P. blatchfordae, P. brassicacearum, P. brenneri, P. cedrina, P. corrugata, P. fluorescens, P. gessardii, P. libanensis, P. mandelii, P. marginalis, P. mediterranea, P. meridiana, P. migulae, P. mucidolens, P. orientalis, P. panacis, P. proteolytica, P. rhodesiae, P. synxantha, P. thivervalensis, P. tolaasii, P. veronii, P. denitrificans, P. pertucinogena, P. cremoricolorata, P. fulva, P. monteilii, P. mosselii, P. parafulva, P. putida, P. balearica, P. stutzeri, P. amygdali, P. avellanae, P. caricapapayae, P. cichorii, P. coronafaciens, P. ficuserectae, P. helianthi, P. meliae, P. savastanoi, P. syringae, P. tomato, P. viridiflava, P. abietaniphila, P. acidophila, P. agarici, P. alcaliphila, P. alkanolytica, P. amyloderamosa, P. asplenii, P. azotifigens, P. cannabina, P. coenobios, P. congelans, P. costantinii, P. cruciviae, P. delhiensis, P. excibis, P. extremorientalis, P. frederiksbergensis, P. fuscovaginae, P. gelidicola, P. grimontii, P. indica, P. jessenii, P. jinjuensis, P. kilonensis, P. knackmussii, P. koreensis, P. lini, P. lutea, P. moraviensis, P. otitidis, P. pachastrellae, P. palleroniana, P. papaveris, P. peli, P. perolens, P. poae, P. pohangensis, P. psychrophila, P. psychrotolerans, P. rathonis, P. reptilivora, P. resiniphila, P. rhizosphaerae, P. rubescens, P. salomonii, P. segitis, P. septica, P. simiae, P. suis, P. thermotolerans, P. aeruginosa, P. tremae, P. trivialis, P. turbinellae, P. tuticorinensis, P. umsongensis, P. vancouverensis, P. vranovensis, P. xanthomarina, Ralstonia eutropha, Rhodospirillum rubrum, Rhodobacter sphaeroides, Saccharomyces cerevisiae, Yarrowia lipolytica and Zymomonas mobile. More in particular, the cell may be a bacterial cell selected from the group consisting of Pseudomonas, Corynebacterium, Bacillus and Escherichia. Even more in particular, the cells may be selected from the group consisting of Pseudomonas putida and Escherichia coli.

(28) The genetically modified cell may be genetically different from the wild type cell. The genetic difference between the genetically modified cell according to any aspect of the present invention and the wild type cell may be in the presence of a complete gene, amino acid, nucleotide etc. in the genetically modified cell that may be absent in the wild type cell. In one example, the genetically modified cell according to any aspect of the present invention may comprise enzymes that enable the cell to produce at least one fatty acid and/or acyl coenzyme A thereof; and convert the fatty acid and/or acyl coenzyme A thereof to the fatty acid ester. The wild type cell relative to the genetically modified cell of the present invention may have none or no detectable activity of the enzymes that enable the genetically modified cell to produce at least one fatty acid and/or acyl coenzyme A thereof; and the enzymes that enable genetically modified cell to convert the fatty acid and/or acyl coenzyme A thereof to the respective fatty acid ester.

(29) The phrase wild type as used herein in conjunction with a cell may denote a cell with a genome make-up that is in a form as seen naturally in the wild. The term may be applicable for both the whole cell and for individual genes. The term wild type therefore does not include such cells or such genes where the gene sequences have been altered at least partially by man using recombinant methods.

(30) A skilled person would be able to use any method known in the art to genetically modify a cell. According to any aspect of the present invention, the genetically modified cell may be genetically modified so that in a defined time interval, within 2 hours, in particular within 8 hours or 24 hours, it forms at least twice, especially at least 10 times, at least 100 times, at least 1000 times or at least 10000 times more fatty acid and/or acyl coenzyme A thereof and the respective fatty acid ester than the wild-type cell. The increase in product formation can be determined for example by cultivating the cell according to any aspect of the present invention and the wild-type cell each separately under the same conditions (same cell density, same nutrient medium, same culture conditions) for a specified time interval in a suitable nutrient medium and then determining the amount of target product (fatty acid, acyl coenzyme A thereof and the respective fatty acid ester) in the nutrient medium.

(31) In particular, the cell comprises at least one first genetic mutation that enables the cell to produce at least one fatty acid and/or acyl coenzyme A thereof. In particular, the first genetic mutation may enable the cell to produce at least one fatty acid and/or acyl coenzyme A thereof by means of a malonyl-CoA dependent and malonyl-ACP independent fatty acyl-CoA metabolic pathway. More in particular, there is an increase in enzymatic activity in the malonyl-CoA dependent and malonyl-ACP independent fatty acyl-CoA metabolic pathway in the cell relative to the wild type cell.

(32) The cell may be genetically modified for increased enzymatic activity in the microorganism's malonyl-CoA dependent, malonyl-ACP independent, fatty acyl-CoA metabolic pathway (MDMIFAA) This pathway is also referred to herein as malonyl-CoA dependent, but malonyl-ACP independent, fatty acyl-CoA metabolic pathway. Such increase in the cell's malonyl-CoA dependent, malonyl-ACP independent fatty acyl-CoA metabolic pathway can be achieved by an increased activity or expression of a gene or a pathway comprising an acetoacetyl-CoA synthase, a ketoacyl-CoA synthase (or elongase), an enoyl-CoA reductase, a ketoacyl-CoA reductase and/or a 3-hydroxyacyl-CoA dehydratase in combination with a decrease in expression or activity of acetoacetyl-CoA thiolase. Alternatively, increased activity in the microorganism's malonyl-CoA dependent, malonyl-ACP independent fatty acyl-CoA metabolic pathway can be achieved by an increased expression of a gene or a pathway comprising an acetoacetyl-CoA synthase, a ketoacyl-CoA thiolase, a enoyl-CoA reductase, a ketoacyl-CoA reductase and/or a 3-hydroxyacyl-CoA dehydratase in combination with a decrease in expression or activity of acetoacetyl-CoA thiolase.

(33) A list of non-limiting genetic modifications to enzymes or enzymatic activities that may lead a cell to produce a fatty acid and/or acyl coenzyme A thereof and that may be considered as the first genetic mutation according to any aspect of the present invention are provided below in Table 1 and explained in US20140051136.

(34) In particular, fatty acid biosynthetic pathways in the cells of the present invention use precursors acetyl-CoA and malonyl-CoA. The enzymes that may be involved are provided in FIG. 11.

(35) In one example, nucleic acid sequences that encode temperature-sensitive forms of these polypeptides may be introduced in place of the native enzymes, and when such genetically modified microorganisms are cultured at elevated temperatures (at which these thermolabile polypeptides become inactivated, partially or completely, due to alterations in protein structure or complete denaturation), there is observed an increase in a chemical product. For example, in E. coli, these temperature-sensitive mutant genes could include FabIts(S241F), FabBts(A329V) or FabDts(W257Q) amongst others. In most of these examples, the genetic modifications may increase malonyl-CoA utilization so that there is a reduced conversion of malonyl-CoA to fatty acids via the native pathway, overall biomass, and proportionally greater conversion of carbon source to a chemical product including a fatty acid or fatty acid derived product via a malonyl-CoA dependent and malonyl-ACP independent route. Also, additional genetic modifications, such as to increase malonyl-CoA production, may be made for some examples.

(36) In another example, the enzyme, enoyl-acyl carrier protein reductase (EC No. 1.3.1.9, also referred to as enoyl-ACP reductase) is a key enzyme for fatty acid biosynthesis from malonyl-CoA. In Escherichia coli this enzyme, FabI, is encoded by the gene FabI (Richard J. Heath et al., 1995).

(37) In one example, the expression levels of a pyruvate oxidase gene (Chang et al., 1983, Abdel-Ahmid et al., 2001) can be reduced or functionally deleted in the cell according to any aspect of the present invention. The pyruvate oxidase gene may encode an enzyme of, for example, EC 1.2.3.3. In particular, the pyruvate oxidase gene may be a PoxB gene.

(38) In one example, the expression levels of a lactate dehydrogenase gene (Mat-Jan et al., Bunch et al., 1997) can be reduced or functionally deleted. In some examples, the lactate dehydrogenase gene encodes an enzyme of, for example, EC 1.1.1.27. The lactate dehydrogenase gene may be an NAD-linked fermentative D-lactate dehydrogenase gene. In particular, the lactate dehydrogenase gene is an IdhA gene.

(39) In one example, the first genetic mutation may be in at least one feedback resistant enzyme of the cell that results in increased expression of the feedback resistant enzyme. In particular, the enzyme may be pantothenate kinase, pyruvate dehydrogenase or the like. In E. coli, these feedback resistant mutant genes could include CoaA(R106A) and/or lpd(E354K).

(40) In a further example, the increase in the cell's malonyl-CoA dependent, but malonyl-ACP independent fatty acyl-CoA metabolic pathway may occur through reduction in the acetoacetyl-CoA thiolase activity and/or trigger factor activity and/or in the activity of a molecular chaperone involved in cell division. In one example, the cell may comprise a genetic mutation in Ttig gene.

(41) In one example, the first genetic mutation in the cell may result in increased enzymatic activity in the NADPH-dependent transhydrogenase pathway relative to the wild type cell. This result may occur by introduction of a heterologous nucleic acid sequence coding for a polypeptide encoding nucleotide transhydrogenase activity.

(42) In another example, the first genetic mutation in the cell may result in decreased expression of fatty acyl-CoA synthetase and/or ligase activity via any method known in the art.

(43) In yet another example, the first genetic mutation in the cell may result in overexpression of an enzyme having acetyl-CoA carboxylase activity.

(44) In one example, the cell may have increased intracellular bicarbonate levels brought about by introduction of a heterologous nucleic acid sequence coding for a polypeptide having cyanase and/or carbonic anhydrase activity.

(45) More in particular, the first genetic mutation according to any aspect of the cell may result in increased and/or decreased levels of fatty acyl-CoA thioesterase activity. This result may increase chain length specificity of a desired fatty acid product by increasing levels of chain length specific fatty acyl-CoA thioesterase activity and decreasing the activity of fatty acyl-CoA thioesterase activity on undesired fatty acid chain lengths. In one example, the increased chain length specificity of fatty acid or fatty acid derived product may occur by increasing levels of chain length specific ketoacyl-CoA thiolase, enoyl-CoA reductase, ketoacyl-CoA reductase or 3-hydroxyacyl-CoA dehydratase activities either individually or in combination.

(46) The first genetic mutation in the cell according to any aspect of the present invention may result in an increase or decrease in expression of only one enzyme selected from the list of enzymes mentioned above or an increase or decrease in expression of a combination of enzymes mentioned above.

(47) In another example, the first genetic mutation in the cell may be in at least one enzyme selected from the group consisting of acetoacetyl-CoA synthase, ketoacyl-CoA synthase (or elongase), enoyl-CoA reductase, ketoacyl-CoA reductase, 3-hydroxyacyl-CoA dehydratase and acetoacetyl-CoA thiolase. More in particular, the first genetic mutation in the cell may result in an increase in expression of acetoacetyl-CoA synthase, ketoacyl-CoA synthase (or elongase), enoyl-CoA reductase, ketoacyl-CoA reductase and 3-hydroxyacyl-CoA dehydratase in combination optionally with a decrease in expression or activity of acetoacetyl-CoA thiolase. In particular, the enoyl-CoA reductase and/or ketoacyl-CoA reductase may either utilize the cofactor NADH and/or NADPH. In particular, the genetic modification in the cell according to any aspect of the present invention may comprise any of the enzymes listed in Table 1 in combination with the following enzymes acetoacetyl-CoA synthase, ketoacyl-CoA synthase (or elongase), enoyl-CoA reductase, ketoacyl-CoA reductase and/or 3-hydroxyacyl-CoA dehydratase and acetoacetyl-CoA thiolase wherein the expression or activity of enzymes acetoacetyl-CoA synthase, ketoacyl-CoA synthase (or elongase), enoyl-CoA reductase, ketoacyl-CoA reductase and 3-hydroxyacyl-CoA dehydratase is increased and the activity of acetoacetyl-CoA thiolase is decreased.

(48) In yet another example, malonyl-CoA dependent, malonyl-ACP independent fatty acyl-CoA metabolic pathway in the cell according to any aspect of the present invention can be achieved by an increased expression of a gene or a pathway comprising acetoacetyl-CoA synthase, ketoacyl-CoA thiolase, enoyl-CoA reductase, ketoacyl-CoA reductase and/or 3-hydroxyacyl-CoA dehydratase in combination with a decrease in expression or activity of acetoacetyl-CoA thiolase.

(49) In particular, the first genetic modification in the cell according to any aspect of the present invention may comprise any of the enzymes listed in Table 1 in combination with the following enzymes acetoacetyl-CoA synthase, ketoacyl-CoA thiolase, enoyl-CoA reductase, ketoacyl-CoA reductase and/or 3-hydroxyacyl-CoA dehydratase in combination with a decrease in expression or activity of acetoacetyl-CoA thiolase.

(50) In one example, the cell according to any aspect of the present invention may comprise a first genetic modification in any of the enzymes listed in Table 1 in combination with the following enzymes acetyl-CoA carboxylase, malonyl-CoA:ACP transacylase (FabD), -ketoacyl-ACP synthase III, -ketoacyl-ACP synthase I (FabB), -ketoacyl-ACP synthase II (FabF), 3-oxoacyl-ACP-synthase I and enoyl ACP reductase.

(51) More in particular, the first genetic mutation may result in an increase in the expression of at least one enzyme selected from the group consisting of acetyl-CoA carboxylase, malonyl-CoA:ACP transacylase (FabD), -ketoacyl-ACP synthase III, -ketoacyl-ACP synthase I (FabB), -ketoacyl-ACP synthase II (FabF), 3-oxoacyl-ACP-synthase I and enoyl ACP reductase relative to the wild type cell. In particular, the first genetic mutation may result in an increase in the expression of more than one enzyme in the cell according to any aspect of the present invention that enables the cell to produce a fatty acid and/or acyl coenzyme A thereof by means of increased enzymatic activity in the cell relative to the wild type cell of malonyl-CoA dependent and malonyl-ACP independent fatty acyl-CoA metabolic pathway.

(52) In one example, there may be an increase in expression of -ketoacyl-ACP synthase and 3-oxoacyl-ACP-synthase in the cell according to any aspect of the present invention. In another example, there may be an increase in expression of -ketoacyl-ACP synthase and Malonyl-CoA-ACP transacylase in the cell according to any aspect of the present invention. In yet another example, there may be an increase in expression of -ketoacyl-ACP synthase and enoyl ACP reductase in the cell according to any aspect of the present invention. In one example, there may be an increase in expression of -ketoacyl-ACP synthase, Malonyl-CoA-ACP transacylase and enoyl ACP reductase in the cell according to any aspect of the present invention. In all examples, there may be an increase in the expression of enoyl ACP reductase and/or acyl-CoA thioesterase.

(53) The phrase increased activity of an enzyme, as used herein is to be understood as increased intracellular activity. Basically, an increase in enzymatic activity can be achieved by increasing the copy number of the gene sequence or gene sequences that code for the enzyme, using a strong promoter or employing a gene or allele that code for a corresponding enzyme with increased activity and optionally by combining these measures. Genetically modified cells used according to any aspect of the present invention are for example produced by transformation, transduction, conjugation or a combination of these methods with a vector that contains the desired gene, an allele of this gene or parts thereof and a vector that makes expression of the gene possible. Heterologous expression is in particular achieved by integration of the gene or of the alleles in the chromosome of the cell or an extra-chromosomally replicating vector.

(54) Accordingly, the cells and methods of the present invention may comprise providing a genetically modified microorganism that comprises both a production pathway to a fatty acid or fatty acid derived product, and a modified polynucleotide that encodes an enzyme of the malonyl-ACP dependent fatty acid synthase system that exhibits reduced activity, so that utilization of malonyl-CoA shifts toward the production pathway compared with a comparable (control) microorganism lacking such modifications. The methods involve producing the chemical product using a population of such genetically modified microorganism in a vessel, provided with a nutrient media. Other genetic modifications described herein, to other enzymes, such as acetyl-CoA carboxylase and/or NADPH-dependent transhydrogenase, may be present in some such examples. Providing additional copies of polynucleotides that encode polypeptides exhibiting these enzymatic activities is shown to increase a fatty acid or fatty acid derived product production. Other ways to increase these respective enzymatic activities is known in the art and may be applied to various examples of the present invention.

(55) TABLE-US-00001 TABLE 1 Examples of genetic modifications in cells of microorganisms for production of fatty acids and/or acyl coenzyme A thereof Genetic Modifications E.C. CLASSIFICATION GENE NAME ENZYME FUNCTION No. IN E. COLI COMMENTS Glucose transporter N/A galP Increase function Pyruvate dehydrogenase E1p 1.2.4.1 aceE Increase function lipoate acetyltransferase/ 2.3.1.12 aceF Increase function dihydrolipoamide acetyltransferase Pyruvate dehydrogenase 1.8.1.4 lpd Increase function or E3 (lipoamide dehydrogenase) alter such as by mutation to increase resistance to NADH inhibition. Lactate dehydrogenase 1.1.1.28 ldhA Decrease function, including by mutation Pyruvate formate lyase 2.3.1. pflB Decrease function, (B inactive) including by mutation Pyruvate oxidase 1.2.2.2 poxB Decrease function, including by mutation Phosphate acetyltransferase 2.3.1.8 Pta Decrease function, including by mutation acetate kinase 2.7.2.15 2.7.2.1 ackA Decrease function, including by mutation methylglyoxal synthase 4.2.3.3 mgsA Decrease function, including by mutation Heat stable, histidyl N/A ptsH Decrease function, phosphorylatable protein (of PTS) (HPr) including by mutation Phosphoryl transfer protein N/A ptsI Decrease function, (of PTS) including by mutation Polypeptide chain (of PTS) N/A Crr Decrease function, including by mutation 3-oxoacyl-ACP synthase I 2.3.1.179 fabF Decrease function, 3-oxoacyl-ACP synthase II 2.3.1.41 including by mutation monomer -ketoacyl-ACP synthase I, 2.3.1.41 fabB Decrease function, 3-oxoacyl-ACP-synthase I 2.3.1. including by mutation Malonyl-CoA-ACP 2.3.1.39 fabD Decrease function, transacylase including by mutation enoyl acyl carrier protein 1.3.1.9. fabI Decrease function, reductase 1.3.1.10 including by mutation -ketoacyl-acyl carrier 2.3.1.180 fabH Decrease function, protein synthase III including by mutation Carboxyl transferase 6.4.1.2 accA Increase function subunit subunit Biotin carboxyl carrier 6.4.1.2 accB Increase function protein Biotin carboxylase subunit 6.3.4.14 accC Increase function Carboxyl transferase 6.4.1.2 accD Increase function subunit subunit long chain fatty acyl 3.1.2.2. tesA Increase function as thioesterase I 3.1.1.5 well as alter by mutation to express in cytoplasm or deletion acyl-CoA synthase 2.3.1.86 fadD Decrease via deletion or mutation acetate CoA-transferase 2.8.3.8 atoD Decrease via deletion or mutation acetate CoA-transferase 2.8.3.8 atoA Decrease via deletion or mutation Transporter N/A atoB Decrease via deletion or mutation acetyl-CoA acetyltransferase 2.3.1.9 atoB Decrease via deletion or mutation pantothenate kinase 2.7.1.33 coaA Increase via expression or feedback resisant mutation lactose repressor N/A lacI Decrease via deletion or mutation -glutamyl-- 1.2.1. puuC Decrease via deletion aminobutymidehyrte or mutation dehydrogenase malate synthase A 2.3.3.9 aceB Decrease via deletion or mutation isocitrate lyase 4.1.3.1 aceA Decrease via deletion or mutation isocitrate dehydrogenase 3.1.3. aceK Decrease via deletion phosphatase/isocitrate 2.7.11.5. or mutation dehydrogenase kinase pyruvate formate-lyase 1.2.1.10 1.1.1.1 adhE Decrease via deletion deactivate or mutation aldehyde dehydrogenase A, 1.2.1.21 1.2.1.22 aldA Decrease via deletion NAD-linked or mutation acetaldehyde 1.2.1.4 aldB Decrease via deletion dehydrogenase or mutation Lambda phage DE3 lysogen N/A DE3 Increase T7 mRNA polymerase N/A T7pol Increase trigger factor 5.2.1.8 tig Decrease via deletion or mutation 3-ketoacyl-CoA thiolase 2.3.1.16 fadA Increase dodecenoyl-CoA -isomerase, 5.3.3.8 1.1.1.35 fadB Increase enoyl-CoA hydratase, 3- 5.1.2.3 4.2.1.17 hydroxybutyryl-CoA epimerase, 3-hydroxyacyl-CoA dehydrogenase Sucrose permease N/A cscB Increase Invertase 3.2.1.26 cscA Increase fructokinase 2.7.1.4 cscK Increase carbonic anhydrase 4.2.1.1 cynT Increase carbonic anhydrase 4.2.1.1 can Increase pyridine nucleotide 1.6.1.2 pntAB Increase transhydrogenase pyridine nucleotide 1.6.1.1 udhA Increase transhydrogenase acyl-CoA thioesterase 3.1.2.20 3.1.2.2 yciA Increase and or decrease thioesterase II 3.1.2.20 3.1.2.2 tesB Increase and or decrease thioesterase III 3.1.2. fadM Increase and or decrease hydroxyphenylacetyl-CoA N/A paaI Increase and or thioesterase decrease esterase/thioesterase 3.1.2.28 ybgC Increase and or decrease proofreading thioesterase in entH Increase and or enterobactin biosynthesis decrease acetoacetyl-CoA synthase 2.3.1.194 npth07 Increase 3-ketoacyl-CoA synthase/elongase 2.3.1 Elo1 Increase 3-ketoacyl-CoA synthase/elongase 2.3.1 Elo2 Increase 3-Hydroxybutyryl-CoA dehydrogenase 1.1.1.157 hbd Increase 3-oxoacyl-CoA reductase 1.1.1.100 fabG Increase enoyl-CoA hydratase 4.2.1.17 crt Increase enoyl-CoA hydratase 4.2.1.17 ech2 Increase Trans-2-enoyl-reductase 1.3.1.9 ter Increase thioesterase 3.1.2.20 paaI Decrease E.C. No = Enzyme Commission number

(56) Also, without being limiting, a first step in some multi-phase methods of making a fatty acid may be exemplified by providing into a vessel, such as a culture or bioreactor vessel, a nutrient media, such as a minimal media as known to those skilled in the art, and an inoculum of a genetically modified microorganism so as to provide a population of such microorganism, such as a bacterium, and more particularly a member of the family Enterobacteriaceae, such as E. coli, where the genetically modified microorganism comprises a metabolic pathway that converts malonyl-CoA to a fatty acid. This inoculum is cultured in the vessel so that the cell density increases to a cell density suitable for reaching a production level of a fatty acid or fatty acid derived product that meets overall productivity metrics taking into consideration the next step of the method. In various alternative embodiments, a population of these genetically modified microorganisms may be cultured to a first cell density in a first, preparatory vessel, and then transferred to the noted vessel so as to provide the selected cell density. Numerous multi-vessel culturing strategies are known to those skilled in the art. Any such examples provide the selected cell density according to the first noted step of the method.

(57) Also without being limiting, a subsequent step may be exemplified by two approaches, which also may be practiced in combination in various examples. A first approach provides a genetic modification to the genetically modified microorganism such that its enoyl-ACP reductase enzymatic activity may be controlled. As one example, a genetic modification may be made to substitute a temperature-sensitive mutant enoyl-ACP reductase (e.g., fabI.sup.TS in E. coli) for the native enoyl-ACP reductase. The former may exhibit reduced enzymatic activity at temperatures above 30 C. but normal enzymatic activity at 30 C., so that elevating the culture temperature to, for example to 34 C., 35 C., 36 C., 37 C. or even 42 C., reduces enzymatic activity of enoyl-ACP reductase. In such case, more malonyl-CoA is converted to a fatty acid than at 30 C., where conversion of malonyl-CoA to fatty acids is not impeded by a less effective enoyl-ACP reductase.

(58) Other genetic modifications that may be useful in the production of fatty acids may be included in the cell. For example, the ability to utilize sucrose may be provided, and this would expand the range of feed stocks that can be utilized to produce a fatty acid or fatty acid derived product or other chemical products. Common laboratory and industrial strains of E. coli, such as the strains described herein, are not capable of utilizing sucrose as the sole carbon source. Since sucrose, and sucrose-containing feed stocks such as molasses, are abundant and often used as feed stocks for the production by microbial fermentation, adding appropriate genetic modifications to permit uptake and use of sucrose may be practiced in strains having other features as provided herein. Various sucrose uptake and metabolism systems are known in the art (for example, U.S. Pat. No. 6,960,455).

(59) Also, genetic modifications may be provided to add functionality for breakdown of more complex carbon sources, such as cellulosic biomass or products thereof, for uptake, and/or for utilization of such carbon sources. For example, numerous cellulases and cellulase-based cellulose degradation systems have been studied and characterized (Beguin, P and Aubert, J-P, 1994; Ohima, K. et al., 1997.)

(60) In some examples, genetic modifications increase the pool and availability of the cofactor NADPH, and/or, consequently, the NADPH/NADP.sup.+ ratio may also be provided. For example, in E. coli, this may be done by increasing activity, such as by genetic modification, of one or more of the following genes: pgi (in a mutated form), pntAB, overexpressed, gapA:gapN substitution/replacement, and disrupting or modifying a soluble transhydrogenase such as sthA, and/or genetic modifications of one or more of zwf, gnd, and edd.

(61) Any such genetic modifications may be provided to species not having such functionality, or having a less than desired level of such functionality. More generally, and depending on the particular metabolic pathways of a microorganism selected for genetic modification, any subgroup of genetic modifications may be made to decrease cellular production of fermentation product(s) selected from the group consisting of acetate, acetoin, acetone, acrylic, malate, fatty acid ethyl esters, isoprenoids, glycerol, ethylene glycol, ethylene, propylene, butylene, isobutylene, ethyl acetate, vinyl acetate, other acetates, 1,4-butanediol, 2,3-butanediol, butanol, isobutanol, sec-butanol, butyrate, isobutyrate, 2-OH-isobutyrate, 3-OH-butyrate, ethanol, isopropanol, D-lactate, L-lactate, pyruvate, itaconate, levulinate, glucarate, glutarate, caprolactam, adipic acid, propanol, isopropanol, fusel alcohols, and 1,2-propanediol, 1,3-propanediol, formate, fumaric acid, propionic acid, succinic acid, valeric acid, and maleic acid. Gene deletions may be made as disclosed generally herein, and other approaches may also be used to achieve a desired decreased cellular production of selected fermentation products.

(62) The first genetic mutation according to any aspect of the present invention may result in the formation of at least one fatty acid and/or acyl coenzyme A (CoA) thereof, wherein the fatty acid comprises at least 5 carbon atoms. In particular, the fatty acid may be of any chain length from 5 to greater than 18 carbons. The fatty acid may be selected from the group consisting of: pentanoic acid, hexanoic acid, octanoic acid, decanoic acid, dodecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, and oleic acid. In particular, these fatty acids may be produced from a fatty acyl-CoA intermediate via the activity of a fatty acyl-CoA thioesterase. Alternatively, these fatty acids may be produced from a fatty acyl-CoA intermediate via concerted activities of a fatty acyl-CoA phosphotransferase first producing a fatty acyl-phosphate and then the action of a fatty acid kinase operating to produce a fatty acid from the fatty acyl-phosphate.

(63) According to any aspect of the present invention the cell according to any aspect of the present invention may be combined with a carbon source to be able to produce the fatty acid. In particular, the carbon source provided to the cell may have a ratio of carbon-14 to carbon-12 of about 1.010.sup.14 or greater. The carbon source may be selected from the group consisting of glucose, sucrose, fructose, dextrose, lactose, xylose, pentose, polyol, hexose, other cellulosic sugars or a combination thereof. In one example, the carbon source may be glycerol. In another example, the carbon source may be synthesis gas. Synthesis gas can for example be produced as a by-product of coal gasification. Accordingly, the microorganism according to any aspect of the present invention may be capable of converting a substance which is a waste product into a valuable resource.

(64) In another example, synthesis gas may be a by-product of gasification of widely available, low-cost agricultural raw materials for use with the mixed culture of the present invention to produce substituted and unsubstituted organic compounds. There are numerous examples of raw materials that can be converted into synthesis gas, as almost all forms of vegetation can be used for this purpose. In particular, raw materials are selected from the group consisting of perennial grasses such as miscanthus, corn residues, processing waste such as sawdust and the like.

(65) In general, synthesis gas may be obtained in a gasification apparatus of dried biomass, mainly through pyrolysis, partial oxidation and steam reforming, wherein the primary products of the synthesis gas are CO, H.sub.2 and CO.sub.2. Usually, a portion of the synthesis gas obtained from the gasification process is first processed in order to optimize product yields, and to avoid formation of tar. Cracking of the undesired tar and CO in the synthesis gas may be carried out using lime and/or dolomite. These processes are described in detail in for example, Reed, 1981.

(66) In particular, the cell culture may comprise an inhibitor of fatty acid synthase the cell may be genetically modified for reduced enzymatic activity in the cell's fatty acid synthase pathway. This may allow better control for producing the specific desired fatty acid.

(67) The cell according to any aspect of the present invention may comprise at least one second genetic mutation that may increase the activity of at least one wax ester synthase in the cell relative to the wild type cell. The wax ester synthase may comprise sequence identity of at least 50% to a polypeptide of SEQ ID NOs: 1-23 and combinations thereof or to a functional fragment of any of the polypeptides for catalyzing the conversion of fatty acid and/or acyl coenzyme A thereof to the respective fatty acid ester. In particular, the wax ester synthase may comprise sequence identity of at least 50% to a polypeptide of SEQ ID NOs: 1-8 and combinations thereof. More in particular, the wax ester synthase used according to any aspect of the present invention may comprise sequence identity of at least 60, 65, 70, 75, 80, 85, 90, 95, 98 or 100% to a polypeptide of any one of sequences of SEQ ID NOs: 1-8 and combinations thereof. These sequences are only reference amino acid sequences. In particular, the sequence of the wax ester synthase used according to any aspect of the present invention may comprise amino acids other than those essential for the function, for example the catalytic activity of a protein, or the fold or structure of a molecule are deleted, substituted or replaced by insertions or essential amino acids are replaced in a conservative manner to the effect that the biological activity of the reference sequence or a molecule derived therefrom is preserved. The state of the art comprises algorithms that may be used to align two given amino acid sequences and to calculate the degree of identity, see Arthur Lesk (2008), and Katoh et al., 2005. In particular, the wax ester synthase sequences used according to any aspect of the present invention may comprise the amino acids that provide the function to the protein. More in particular, the wax ester synthase sequences may comprise deletions, insertions or substitutions in amino acid sequences as well as fusions that still retain the function of the wax ester synthase capable of catalyzing the conversion of fatty acid and/or acyl coenzyme A thereof to the respective fatty acid ester. In one example, a mutant of any one of the sequences of SEQ ID NO:1-8 may be used in any aspect of the present invention. A mutant used herein indicates a mutant derived from any one of the sequences of SEQ ID NO:1-8 that is capable of maintaining the function of a wax ester synthase of converting a fatty acid and/or acyl coenzyme A thereof to the respective fatty acid ester. Such a mutant has an amino acid sequence subjected to deletion, substitution, insertion, or addition of at least one amino acid. The mutant of the present invention can be adequately produced with the use of any methods known to persons skilled in the art.

(68) TABLE-US-00002 TABLE2 Sequenceofwaxestersynthases AccessionNo. SEQIDNO: (NCBI) Organism Sequence 1 522136843 Singularimonas MESPRTPMHVGGLMTFRLPPD (Svar) variicoloris APPDFLRQLFARLRAQMPSTEP FNLRLARTPWSALAPAWEPAP DIDIDYHVRHSALPYPGGEREL GVLVSRLHSHPLDLRRPPWEIT LIEGLENDRFAFFLKVHHSALD GMGALKLVRRWLSADALQRD MPALWALPAQPREARDAPHGH AVEQGVEALRTQLRASGELLST LRRMARRRDNPEGGILSALSTP RTLLNVPITPQRRLATQLFELSR IKAVSAATQSTVNDVALALIAG AVRRYLLELDALPHEPLVASVP VGLPRADGKPGNAVAGFVVPL ETQADDPLDCLHVVRAVTQRT KDQLRGMSPEALAQFTMLGLS PLILGQMARVLSHLPPIFNFVVS NVVASKELLYLEGAELEAMYPI SVLFDGYALNVTLVGYHDRLS LGFTGCRDALPSLQRLAVYSAE ALEELERAAGLVPHAAGAAEH APARRTRRRGAH 2 YP_436128.1 Hahella MTPLSPVDQIFLWLEKRQQPM (Hche) chejuensis HVGGLHIFSFPDDADAKYMTEL KCTC2396 AQQLRAYATPQAPFNRRLRQR WGRYYWDTDAQFDLEHHFRH EALPKPGRIRELLAHVSAEHSN LMDRERPMWECHLIEGIRGRRF AVYYKAHHCMLDGVAAMRM CVKSYSFDPTATEMPPIWAISK DVTPARETQAPAAGDLVHSLS QLVEGAGRQLATVPTLIRELGK NLLKARDDSDAGLIFRAPPSILN QRITGSRRFAAQSYALERFKAI GKAFQATVNDVVLAVCGSALR NYLLSRQALPDQPLIAMAPMSI RQDDSDSGNQIAMILANLGTHI ADPVRRLELTQASARESKERFR QMTPEEAVNYTALTLAPSGLNL LTGLAPKWQAFNVVISNVPGPN KPLYWNGARLEGMYPVSIPVD YAALNITLVSYRDQLEFGFTAC RRTLPSMQRLLDYIEQGIAELE KAAGV 3 480024154 Acinetobacter MRPLHPIDFIFLSLEKRQQPMH (Ajun) juniiNIPH182 VGGLFLFEIPENASPTFVHDLVQ DIRQSKSIPVPPFNNQLNGLFW GEDPEFDIDHHFRHIALPNPGRI RELLVYISQQHSSLIDRAKPLW TCDIIEGIEGNRFAMYFKIHHA MVDGVAGMRLIEKSLSKDPNE KHVVPLWCVEGKRTKRLKAPK PPSVSKIKGIMDGIKSQLEVTPK VMQELSQTIFKEIGKNPDYVST FQAPPSILNQRVSSSRRFAAQSF ELDRFRNIAKSLGVTINDVVLA VCAGALREYLISHESLPKKPLIA MVPASLRTDDSDVSNRITMILA NLATHIEDPIERLQIIRRSVQNSK QRFSRMTANEILNYSALVYGPA GLNIVSGMLPKRQAFNLVISNV PGPREPLYWNGAKLDALYPASI VMDGQALNITMTSYLDKLEVG LIACRNALPKMQNLLTHLEDEI QRFESAILSLPKQAAEG 4 449424446 Amycolatopsis MPFMPVTDSMFLLVETREHPM (Aazu) azureaDSM HVGGLQLFKKPEDAGPDYLRD 43854 LRRKLLDSDNMRDVFRRRPAR PVNTAGHVAWATDNDLELDY HFRHSALPQPGRIRELLELTGR WHSTLLDRHRPLWEIHLVEGL QDGRFAIYSKIHHALMDGVSAL RHLQGTLSDDPTDLDCPPPWGR RPKPDGGRNGKASPSVLSTFGK TVNQLAGIAPAAMKVAREAFQ EHTLTLPAQAPKTMLNVPIGGA RRFAAQSWSLDRVRKVATAAG VSRNDVVLAMCSGALRDYLIE QNSLPDAPLTAMVPVSLRRKDS GDAAGNNIGALLCNLATHLTD PAARLATINASMRNGKKLFSEL TPLQTLLLSGINVAQLGVSPIPG FVNNTKPPFNLVISNVPGPRKQ MYWNGASLDGIYPASVLLDGQ ALNITLTSNGDNLDFGVTGCRR SVPHLQRILTHLDTALAELEHA VSVGRS 5 479966651 Acinetobacter MRPLHPIDFIFLSLEKRQQPMH (Acip) sp.CIP56.2 VGGLFLFELPENASPTFVHDLV NEIRQSKSIPVPPFNNQLNGLFW GEDSEFDLDHHFRHIALPNPGRI RELLVYISQQHSSLIDRAKPLW TCDIIEGIEGNRFAMYFKIHHA MVDGVAGMRLIEKSLSQDPNE KHVVPLWCVEGKRTKRLKAPK PPTVSKIKGVMEGIKSQLEVAP KVMQELSQTIFKEMGKNPDYV STFQAPPSILNQRVSSSRRFAAQ SFELGRFRRIAKSLGVTLNDVIL AVCSGALREYLISHNSLPKKPLI AMVPASLRTDDSDVSNRITMIL ANLATHIEDPIERLEVIRRSVQN SKQRFSRMTANEILNYSAVVYG PAGLNIASGMLPKRQAFNLVIS NVPGPREPLYWNGAKLDALYP ASIVMDGQALNITMTSYLDKLE VGLIACRNALPKMQNLLTHLEE EIQRFEQAIQDLPQKVAN 6 ABO21021 Marinobacter MKRLGTLDASWLAVESEDTPM hydrocarbono- HVGTLQIFSLPEGAPETFLRDM clasticusATCC VTRMKEAGDVAPPWGYKLAW 49840 SGFLGRVIAPAWKVDKDIDLDY HVRHSALPRPGGERELGILVSR LHSNPLDFSRPLWECHVIEGLE NNRFALYTKMHHSMIDGISGV RLMQRVLTTDPERCNMPPPWT VRPHQRRGAKTDKEASVPAAV SQAMDALKLQADMAPRLWQA GNRLVHSVRHPEDGLTAPFTGP VSVLNHRVTAQRRFATQHYQL DRLKNLAHASGGSLNDIVLYLC GTALRRFLAEQNNLPDTPLTAG IPVNIRPADDEGTGTQISFMIAS LATDEADPLNRLQQIKTSTRRA KEHLQKLPKSALTQYTMLLMS PYILQLMSGLGGRMRPVFNVTI SNVPGPEGTLYYEGARLEAMY PVSLIAHGGALNITCLSYAGSLN FGFTGCRDTLPSMQKLAVYTG EALDELESLILPPKKRARTRK 7 YP_957462 Marinobacter MGSSHHHHHHSSGLVPRGSHM (Maqu aquaeoleiVT8 TPLNPTDQLFLWLEKRQQPMH T373M, T373M,Q420R VGLQLFSFPEGAPDDYVAQLA Q420R) DQLRQKTEVTAPFNQRLSYRLG QPVWVEDEHLDLEHHFRFEAL PTPGRIRELLSFVSAEHSHLMDR ERPMWEVHLIEGLKDRQFALY TKVHHSLVDGVSAMRMATRM LSENPDEHGMPPIWDLPCLSRD RGESDGHSLWRSVTHLLGLSG RQLGTIPTVAKELLKTINQARK DPAYDSIFHAPRCMLNQKITGS RRFAAQSWCLKRIRAVCEAYG TTVNDVVTAMCAAALRTYLM NQDALPEKPLVAFVPVSLRRDD SSGGNQVGVILASLHTDVQEAG ERLLKIHHGMEEAKQRYRHMS PEEIVNYTALTLAPAAFHLLTG LAPKWQMFNVVISNVPGPSRPL YWNGAKLEGMYP VSIDMDRLALNMTLTSYNDRV EFGLIGCRRTLPSLQRMLDYLE QGLAELELNAGL 8 YP_957462 Marinobacter MGSSHHHHHSSGLVPRGSHMT (Maqu aquaeoleiVT8 PLNPTDQLFLWLEKRQQPMHV E72K) E72K(nofinal GGLQLFSFPEGAPDDYVAQLA HinHis-tag) DQLRQKTEVTAPFNQRLSYRLG QPVWVKDEHLDLEHHFRFEAL PTPGRIRELLSFVSAEHSHLMDR ERPMWEVHLIEGLKDRQFALY TKVHHSLVDGVSAMRMATRM LSENPDEHGMPPIWDLPCLSRD RGESDGHSLWRSVTHLLGLSG RQLGTIPTVAKELLKTINQARK DPAYDSIFHAPRCMLNQKITGS RRFAAQSWCLKRIRAVCEAYG TTVNDVVTAMCAAALRTYLM NQDALPEKPLVAFVPVSLRRDD SSGGNQVGVILASLHTDVQEAG ERLLKIHHGMEEAKQRYRHMS PEEIVNYTALTLAPAAFHLLTG LAPKWQTFNVVISNVPGPSRPL YWNGAKLEGMYPVSIDMDRL ALNMTLTSYNDQVEFGLIGCRR TLPSLQRMLDYLEQGLAELELN AGL 23(Maqu) YP_957462 Marinobacter MTPLNPTDQLFLWLEKRQQPM aquaeoleiVT8 HVGGLQLFSFPEGAPDDYVAQ LADQLRQKTEVTAPFNQRLSYR LGQPVWVEDEHLDLEHHFRI-th ALPTPGRIRELLSFVSAEHSHLM DRERPMWEVHLIEGLKDRQFA LYTKVHHSLVDGVSAMRMAT RMLSENPDEHGMPPIWDLPCLS RDRGESDGHSLWRSVTHLLGL SGRQLGTIPTVAKELLKTINQA RKDPAYDSIFHAPRCMLNQKIT GSRRFAAQSWCLKRIRAVCEA YGTTVNDVVTAMCAAALRTYL MNQDALPEKPLVAFVPVSLRR DDSSGGNQVGVILASLHTDVQE AGERLLKIHHGMEEAKQRYRH MSPEEIVNYTALTLAPAAFHLL TGLAPKWQTFNVVISNVPGPSR PLYWNGAKLEGMYPVSIDMDR LALNMTLTSYNDQVEFGLIGCR RTLPSLQRMLDYLEQGLAELEL NAGL

(69) Throughout this application, any data base code, unless specified to the contrary, refers to a sequence available from the NCBI data bases, more specifically the version online on 12 Jun. 2014, and comprises, if such sequence is a nucleotide sequence, the polypeptide sequence obtained by translating the former.

(70) The cell according to any aspect of the present invention may comprise a third genetic mutation that reduces the fatty acid degradation capacity of the cell relative to the wild type cell.

(71) Degradation of fatty acids is accomplished by a sequence of enzymatically catalyzed reactions. First of all, fatty acids are taken up and translocated across the cell membrane via a transport/acyl-activation mechanism involving at least one outer membrane protein and one inner membrane-associated protein which has fatty acid-CoA ligase activity, referred to in the case of E. coli as FadL and FadD/FadK, respectively. Inside the cell, the fatty acid to be degraded is subjected to enzymes catalyzing other reactions of the -oxidation pathway. The first intracellular step involves the conversion of acyl-CoA to enoyl-CoA through acyl-CoA dehydrogenase, the latter referred to as FadE in the case of E. coli. The activity of an acyl-CoA dehydrogenase may be assayed as described in the state of art, for example by monitoring the concentration of NADH spectrophotometrically at 340 nm in 100 mM MOPS, pH 7.4, 0.2 mM Enoyl-CoA, 0.4 mM NAD.sup.+. The resulting enoyl-CoA is converted to 3-ketoacyl-CoA via 3-hydroxyacyl-CoA through hydration and oxidation, catalyzed by enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase, referred to as FadB and FadJ in E. coli. Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase activity, more specifically formation of the product NADH may be assayed spectrophotometrically as described in the state of the art, for example as outlined for FadE. Finally, 3-ketoacyl-CoA thiolase, FadA and FadI in E. coli, catalyzes the cleavage of 3-ketoacyl-CoA, to give acetyl-CoA and the input acyl-CoA shortened by two carbon atoms. The activity of ketoacyl-CoA thiolase may be assayed as described in the state of the art, for example in Antonenkov, V., D. et al. (1997) Substrate specificities of 3-oxoacyl-CoA thiolase and sterol carrier protein 2/3-oxoacyl-coa thiolase purified from normal rat liver peroxisomes. Sterol carrier protein 2/3-oxoacyl-CoA thiolase is involved in the metabolism of 2-methyl-branched fatty acids and bile acid intermediates. In one example, the term a cell having a reduced fatty acid degradation capacity, as used herein, refers to a cell having a reduced capability of taking up and/or degrading fatty acids. The fatty acid degradation capacity of a cell may be reduced in various ways. In another example, the cell has, compared to its wild type, a reduced activity of an enzyme involved in the -oxidation pathway. In a further example, the term enzyme involved in the -oxidation pathway, as used herein, refers to an enzyme that interacts directly with a fatty acid or a derivative thereof formed as part of the degradation of said fatty acid via the -oxidation pathway the sequence of reactions effecting the conversion of a fatty acid to acetyl-CoA and the CoA ester of the shortened fatty acid, for example by recognizing the fatty acid or derivative thereof as a substrate, and converts it to a metabolite formed as a part of the -oxidation pathway. More in particular, the reduced fatty acid degradation capacity in the cell according to any aspect of the present invention may be the third genetic mutation which results in a decrease in the expression of at least one enzyme selected from the group consisting of acyl-CoA dehydrogenase, 2,4-dienoyl-CoA reductase, enoyl-CoA hydratase and 3-ketoacyl-CoA thiolase relative to the wild type cell.

(72) For example, the acyl-CoA dehydrogenase is an enzyme involved in the -oxidation pathway as it interacts with fatty acid-CoA and converts fatty acid-CoA ester to enoyl-CoA, which is a metabolite formed as part of the -oxidation. In a further example, the term enzyme involved in the -oxidation pathway, as used herein, comprises any polypeptide from the group comprising acyl-CoA dehydrogenase, enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase and 3-keto-acyl-CoA thiolase. Subsequently, the acyl-CoA synthetase may catalyze the conversion a fatty acid to the CoA ester of a fatty acid, i.e. a molecule, wherein the functional group OH of the carboxy group is replaced with S-CoA, for introducing said fatty acid into the -oxidation pathway. For example, the polypeptides FadD and FadK in E. coli (access code: BAA15609.1) are acyl-CoA dehydrogenases. In an example, the term acyl-CoA dehydrogenase, as used herein, is a polypeptide capable of catalyzing the conversion of an acyl-CoA to enoyl-CoA, as part of the -oxidation pathway. For example, the polypeptide FadE in E. coli (access code: BAA77891.2) is an acyl-CoA dehydrogenase. In one example, the term 2,4-dienoyl-CoA reductase, as used herein, is a polypeptide capable of catalyzing the conversion of the 2,4-dienoyl CoA from an unsaturated fatty acid into enoyl-CoA, as part of the -oxidation pathway. For example, the polypeptide FadH in E. coli is a 2,4-dienoyl-CoA reductase. In an example, the term enoyl-CoA hydratase, as used herein, also referred to as 3-hydroxyacyl-CoA dehydrogenase, refers to a polypeptide capable of catalyzing the conversion of enoyl-CoA to 3-ketoacyl-CoA through hydration and oxidation, as part of the -oxidation pathway. For example, the polypeptides FadB and FadJ in E. coli (access code: BAE77457.1) are enoyl-CoA hydratases. In one example, the term ketoacyl-CoA thiolase, as used herein, refers to a polypeptide capable of catalyzing the conversion of cleaving 3-ketoacyl-CoA, resulting in an acyl-CoA shortened by two carbon atoms and acetyl-CoA, for example as the final step of the -oxidation pathway. For example, the polypeptides FadA and FadI in E. coli (access code: AP009048.1) are ketoacyl-CoA thiolases.

(73) In particular, the cell according to any aspect of the present invention may comprise genetic mutations that result in an increase in the expression of -ketoacyl-ACP synthase III. This may be the first mutation in the cell according to any aspect of the present invention. Any -ketoacyl-ACP synthase III (fabH) known in the art may be used in the method according to any aspect of the present invention. In particular, the fabH may be selected from Table 3a.

(74) TABLE-US-00003 TABLE 3a Possible sources of FabH that may be used to produce fatty acids such as lauric acid. FabH Accession No. Shewanella sp. MR-4 gi|113969844 Shewanella frigidimarina NCIMB 400 gi|114563637 Shewanella sp. ANA-3 gi|117920011 Shewanella amazonensis SB2B gi|119774647 Shewanella sp. W3-18-1 gi|120598458 Shewanella baltica OS185 gi|153001200 Gordonia bronchialis DSM 43247 gi|262201496 Gordonia neofelifaecis NRRL B- gi|326383808 59395 putative Shewanella sp. HN-41 gi|336312046 Rheinheimera sp. A13L gi|336314652 Gordonia araii NBRC 100433 gi|359421305 Gordonia polyisoprenivorans NBRC gi|359767552 16320 Gordonia effusa NBRC 100432 gi|359774344 Alishewanella jeotgali KCTC 22429 gi|375108677 Gordonia otitidis NBRC 100426 gi|377561073 Gordonia sputi NBRC 100414 gi|377565709 Gordonia terrae NBRC 100016 gi|377571475 Gordonia polyisoprenivorans VH2 gi|378716896 Alishewanella agri BL06 gi|393761603 Gordonia sp. KTR9 gi|404214055 Shewanella oneidensis MR-1 gi|414562081 Gordonia hirsuta DSM 44140 gi|441517717 Gordonia sihwensis NBRC 108236 gi|441522685 Gordonia soli NBRC 108243 gi|444431726 Gordonia malaquae gi|495656093 Gordonia sp. NB4-1Y gi|464805365 Thalassolituus oleivorans MIL-1 gi|473830078 Colwellia psychrerythraea 34H gi|71278947 Shewanella denitrificans OS217 gi|91793871 Rheinheimera nanhaiensis E407-8 gi383934006 Acinetobacter sp. CIP 53.82 480152603 Hahella chejuensis KCTC 2396 83645428 Acinetobacter sp. SH024 293608659 Acinetobacter sp. NBRC 10098 359430113 Acinetobacter sp. ADP1 50085221 Acinetobacter ursingii DSM 16037 = 406040759 CIP 107286 Acinetobacter bohemicus ANC 3994 479867614 Candidatus Accumulibacter phosphatis 257092603 clade IIA str. UW-1 blood disease bacterium R229 344167953 Ralstonia solanacearum CMR15 410684104 Marinobacter sp. BSs20148 399545195 Marinobacter algicola DG893 149375225 Ralstonia sp. 5_7_47FAA 309779507 Rubrivivax gelatinosus IL144 383757692 Oceanobacter sp. RED65 94501061 gamma proteobacterium HTCC5015 254447852 Ilumatobacter coccineus YM16-304 470180366 marine gamma proteobacterium 254480565 HTCC2148 Marinobacter aquaeolei VT8 120554511 Alcanivorax sp. DG881 254427265 Hydrocarboniphaga effusa AP103 392950783 Curvibacter putative symbiont of Hydra 260220470 magnipapillata gamma proteobacterium HdN1 304312991 marine gamma proteobacterium 119503170 HTCC2080 gamma proteobacterium IMCC3088 329897271 gamma proteobacterium NOR5-3 254514195 Acinetobacter radioresistens SK82 255318218 Acinetobacter sp. NIPH 899 479953276 Acinetobacter schindleri CIP 107287 480002578 Acinetobacter towneri DSM 14962 = 480029713 CIP 107472 Acinetobacter junii CIP 107470 480007780 Acinetobacter sp. CIP 56.2 479964140 Acinetobacter baumannii AYE 169796586 baumannii MDR-ZJ06 Acinetobacter gerneri DSM 14967 = 479991204 CIP 107464 Acinetobacter bouvetii DSM 14964 = 480043238 CIP 107468 Acinetobacter sp. ANC 3789 479932652 Acinetobacter lwoffii SH145 262375396 Acinetobacter soli NIPH 2899 480019083 Acinetobacter baumannii WC-323 425744072 Acinetobacter calcoaceticus NIPH 13 479856262 Acinetobacter johnsonii SH046 262369694 Acinetobacter haemolyticus CIP 64.3 480080132 Acinetobacter sp. CIP 102529 479942708 Acinetobacter sp. CIP-A165 479879420 Acinetobacter guillouiae CIP 63.46 479909393 Ralstonia solanacearum FQY_4 469776065 Ralstonia solanacearum UW551 83747353

(75) The -ketoacyl-ACP synthase III (FabH) may comprise sequence identity of at least 50% to a polypeptide selected from the group consisting of SEQ ID NOs: 24-27 and combinations thereof or to a functional fragment of any of the polypeptides. In particular, the FabH may comprise sequence identity of at least 50% to a polypeptide of SEQ ID NOs: 24-27 and combinations thereof. More in particular, the FabH used according to any aspect of the present invention may comprise sequence identity of at least 60, 65, 70, 75, 80, 85, 90, 95, 98 or 100% to a polypeptide of any one of sequences of SEQ ID NOs: 24-27 and combinations thereof. More in particular, the cell according to any aspect of the present invention may have a first mutation that comprises a combination of sequences of FabH. For example, the cell according to any aspect of the present invention may be genetically modified to comprise a polypeptide with sequence identity of at least 50, 60, 65, 70, 75, 80, 85, 90, 95, 98 or 100% to a polypeptide of comprising SEQ ID NOs: 24 and 27, SEQ ID NOs: 25 and 27, SEQ ID NOs: 26 and 27 and the like.

(76) These sequences are only reference amino acid sequences. In particular, the sequence of the FabH used according to any aspect of the present invention may comprise amino acids other than those essential for the function, for example the catalytic activity of a protein, or the fold or structure of a molecule are deleted, substituted or replaced by insertions or essential amino acids are replaced in a conservative manner to the effect that the biological activity of the reference sequence or a molecule derived therefrom is preserved.

(77) TABLE-US-00004 TABLE3b SequencesofFabH,crt,Hbdthatmaybeusedinthecellsaccording toanyaspectofthepresentinvention SEQID AccessionNo. NO: (NCBI)/ Organism Sequence 24 WP_014577218.1| Marinobacter MIKAVISGTGLYTPPATISNDE adhaerens LVEAFNQYVELFNAENADAI HP15 ASGDVTPLQPSSSSFIEKASGI KRRHVIDKDGILDPNRMKPYI PDRSNEEPSVQCDMAVTACR EALEQAGKSAEDVDAVIVAC SNLQRAYPAVSIEVQEALGID GFAYDMNVACSSATFGLQAA VNSVENGSARAVLVVSPEICS GHLNFRDRDSHFIFGDACTAI LVEREEDTREGQGFEILGTSL KTKFSNNIRNNFGFLNRADES GVGKPDKLFVQQGRKVFKEV SPLVAETIQKQLQSLSLAPDD LRRMWLHQANLNMNQLIAR KVLGRDATEEEAPVILDEYAN TSSAGSIIAFHKNKDDLVSGD LGVICSFGAGYSIGSVVVRRR 25 ZP_10350240 Alishewanella MQQVVISGSGLFTPQHRISNE agriBL06 ELVQSYNQYVDQFNEEHAAA IAAGEIEALEYSSTEFIEKASGI KARHVLYKDGILDPKIMHPVF RKRGEDELPEMVEMAVQAA TQALAQANKTAADIDLIICAA SNMQRPYPALSVELQQALGA GGYAFDMNVACSSATFAISN AVNAIRGGTAKVVLVVNPEF ASPQVDYRSRDSHFIFGDVCT ATIIEAESSCSSQQAFRILGMR LKTTFSNNIRCDIGYTEHCFTE QDPKAPFFKQQGRKVFKELLP IVADVIQDEMAAQNLAPDDL KRLWLHQANINMNIFAAKKI LGRDPLPEEAPLVLDTYANTA SAGSIIAFHKYQQGLVSGDKA ILCSFGAGYSVGCVVLEKC 26 ENU26638 Acinetobacter MGIRITGTGLFHPTESISNEEL sp.NIPH236 VESLNAYVEQFNQENAEQIA AGEIEALRGSSPEFIEKASGIQ RRYVVEKSGILDPKRLRPRLQ ERSNDELSLQAEWGVIAAKQ AMENAGVTAEDIDVVILACS NMQRAYPAVAIEIQSALGIQG YAYDMNVACSAATFGLKQA YDAVKCGARRVLLLNVEITS GHLDYRTRDAHFIFGDVATA SIIEETETKSGYEILDIHLFTQF SNNIRNNFGFLNRSEDAVVDD KLFRQDGRKVFKEVCPLVAKI ITAQLEKLELTPEQVKRFWLH QANANMNELILKLVVGKEAD LERAPIILDEFANTSSAGVIIA MHRTGEQVNNGEYAVISSFG AGYSVGSIIVQKHIA 27 YP_006031367 Ralstonia MHDVVISGTGLWVAPEVITN solanacearum EELVASFNAYARHYNEANAT Po82 AIAAGTLAAVAESSVEFIEKA SGIRQRYVIDKAGVLDPARM RPRLAPRGDDALSLQAEIGVA AAREALAAAGRDAGDIDMLI CSAANMQRPYPAMGIEIQNA LGADGYAFDMNVACSSATFG LEQAINAVRTGSARVALMVN PEITSGHLAWKDRDCHFIFGD VCTAVVVERADDARAPDQW QVLGTRMATRFSNSIRNNAGF LSRSEDRDPDDRDQLFRQEGR KVFKEVCPMAAEHIAGHLQS LGHAPADVRRFWLHQANLG MNQLIGKRLLGRDASADEAP VILDEFANTASAGSIIAFHRHR ADLQPGDLGLICSFGAGYSIG SVAVRKR 28 AAA95967 Clostridium MELNNVILEKEGKVAVVTIN acetobutylicum RPKALNALNSDTLKEMDYVI ATCC824 GEIENDSEVLAVILTGAGEKS FVAGADISEMKEMNTIEGRKF GILGNKVFRRLELLEKPVIAA VNGFALGGGCEIAMSCDIRIA SSNARFGQPEVGLGITPGFGG TQRLSRLVGMGMAKQLIFTA QNIKADEALRIGLVNKVVEPS ELMNTAKEIANKIVSNAPVAV KLSKQAINRGMQCDIDTALAF ESEAFGECFSTEDQKDAMTAF IEKRKIEGFKNR 29 NP_349314 Clostridium MKKVCVIGAGTMGSGIAQAF acetobutylicum AAKGFENVLRDIKDEFVDRG ATCC824 LDFINKNLSKLVKKGKIEEAT KVEILTRISGTVDLNMAADCD LVIEAAVERMDIKKQIFADLD NICKPETILASNTSSLSITEVAS ATKRPDKVIGMHFFNPAPVM KLVEVIRGIATSQETFDAVKE TSIAIGKDPVEVAEAPGFVVN RILIPMINEAVGILAEGIASVE DIDKAMKLGANHPMGPLELG DFIGLDICLAIMDVLYSETGDS KYRPHTLLKKYVRAGWLGR KSGKGFYDYSK

(78) As used herein, the term fatty ester means an ester. In particular, a fatty ester is any ester made from a fatty acid to produce a fatty acid ester. In one example, a fatty ester contains an A side (i.e., the carbon chain attached to the carboxylate oxygen) and a B side (i.e., the carbon chain comprising the parent carboxylate). In a particular, when the fatty ester is derived from the fatty acid biosynthetic pathway, the A side is contributed by an alcohol, and the B side is contributed by a fatty acid. Any alcohol can be used to form the A side of the fatty esters. For example, the alcohol can be derived from the fatty acid biosynthetic pathway. Alternatively, the alcohol can be produced through non-fatty acid biosynthetic pathways. In one example, the alcohol can be provided exogenously. For example, the alcohol can be supplied in the fermentation broth in instances where the fatty ester is produced by an organism that can also produce the fatty acid. Alternatively, a carboxylic acid, such as a fatty acid or acetic acid, can be supplied exogenously in instances where the fatty ester is produced by an organism that can also produce alcohol.

(79) The carbon chains comprising the A side or B side can be of any length. In one example, the A side of the ester is at least about 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, or 18 carbons in length. The B side of the ester is at least about 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, or 26 carbons in length. The A side and/or the B side can be straight or branched chain. The branched chains may have one or more points of branching. The branched chains may also include cyclic branches and/or the A side and/or B side can be saturated or unsaturated. If unsaturated, the A side and/or B side can have one or more points of unsaturation.

(80) In one example, the fatty ester according to any aspect of the present invention may be produced biosynthetically. In particular, the fatty acid may be activated to produce at least one compound selected from the group consisting of acyl Coenzyme A (acyl-CoA), and acyl phosphate. More in particular, the fatty ester may be activated to Acyl-CoA, a direct product of fatty acid biosynthesis or degradation. Acyl-CoA may also be synthesized from a free fatty acid, a CoA, or an adenosine nucleotide triphosphate (ATP). An example of an enzyme which produces acyl-CoA is acyl-CoA synthase. Acyl-CoA may then be transferred to a recipient nucleophile such as alcohols, thiols, phosphates and the like.

(81) The cell according to any aspect of the present invention may be further genetically modified to increase the expression of 3-hydroxyacyl coenzyme A dehydratase (3HCDh) and/or keto acyl-CoA reductase (KCR) relative to the wild type cell. This is increase in expression may improve the activity of fadB. In particular, the 3HCDh may crotonase/enoyl-CoA hydratase (Crt) and/or the KCR may be hydroxybutyric dehydrogenase (Hbd). More in particular, the Crt may have sequence identity of at least 50, 60, 65, 70, 75, 80, 85, 90, 95, 98 or 100% identity to a polypeptide of SEQ ID NO:28 and/or the Hbd has sequence identity of at least 50, 60, 65, 70, 75, 80, 85, 90, 95, 98 or 100% identity to a polypeptide of SEQ ID NO:29.

(82) In particular, the fatty acid ester may be produced in the presence of at least one exogenous alcohol selected from the group consisting of methanol, ethanol, propanol, butanol, pentanol, hexanol, heptanol, octanol, decanol, dodecanol, tetradecanol, hexadecanol and the like.

(83) More in particular, the fatty acid may be 12 carbons in length. The fatty acid may be lauric acid, the acyl coenzyme A thereof may be lauroyl coenzyme A and the fatty acid ester may be methyl laurate. According to another aspect of the present invention there is provided a method for producing methyl laurate, the method comprising contacting lauric acid and/or lauroyl coenzyme A with an isolated wax ester synthase that has sequence identity of at least 50% to a polypeptide of SEQ ID NOs: 1-8 and combinations thereof. More in particular, the wax ester synthase used according to any aspect of the present invention may comprise sequence identity of at least 60, 65, 70, 75, 80, 85, 90, 95, 98 or 100% to a polypeptide of any one of sequences of SEQ ID NOs: 1-8 and combinations thereof. These sequences are only reference amino acid sequences. In particular, the sequence of the wax ester synthase used according to any aspect of the present invention may comprise amino acids other than those essential for the function, for example the catalytic activity of a protein, or the fold or structure of a molecule are deleted, substituted or replaced by insertions or essential amino acids are replaced in a conservative manner to the effect that the biological activity of the reference sequence or a molecule derived therefrom is preserved.

(84) In particular, the method according to any aspect of the present invention is carried out within the cell according to any aspect of the present invention.

(85) Having generally described this invention, a further understanding can be obtained by reference to certain specific examples which are provided herein for purposes of illustration only, and are not intended to be limiting unless otherwise specified.

(86) The foregoing describes preferred embodiments, which, as will be understood by those skilled in the art, may be subject to variations or modifications in design, construction or operation without departing from the scope of the claims. These variations, for instance, are intended to be covered by the scope of the claims.

EXAMPLES

Example 1

(87) Optimization of C12 Fatty Acyl-CoA Production in E. coli

(88) Production of Fatty Acids Via Malonyl-CoA and Acetyl-CoA in a Shake Flask Experiment

(89) TABLE-US-00005 TABLE 4a List of microorganism strains that were used to produce fatty acids in the subsequent examples. The method of production and the sequences of the strains are provided in Table 3.2 of WO2014026162A1 (OPX Biotechnologies Inc., USA). Strain designation Host Plasmid SEQ ID NOs. BXF_0012 BX_864 1)pBMT-3_ccdAB 30 BXF_0013 BX_864 1)pBMT-3_ccdAB_P.sub.T7- 31 tesA BXF_0014 BX_864 1)pBMT-3_ccdAB_P.sub.T7- 32 nphT7-hbd-crt-ter BXF_0015 BX_864 1)pBMT-3_ccdAB_P.sub.T7- 33 tesA_PT7-nph.sub.T7-hbd-crt- ter BXF_0018 BX_864 pBMT-3_ccdAB_PT7- 32 nphT7-hbd-crt-ter BXF_0020 BX_860 1)pBMT-3_ccdAB_PT7- 33 tesA_PT7-nphT7-hbd-crt- ter BXF_0021 BX_876 1)pBMT-3_ccdAB_PT7- 33 tesA_PT7-nphT7-hbd-crt- ter BXF_0022 BX_874 1)pBMT-3_ccdAB 30 BXF_0023 BX_874 1)pBMT-3_ccdAB_PT7- 31 tesA BXF_0024 BX_874 1)pBMT-3_ccdAB_PT7- 33 tesA_PT7-nphT7-hbd-crt- ter BXF_0025 BX_875 1)pBMT-3_ccdAB 30 BXF_0026 BX_875 1)pBMT-3_ccdAB_PT7- 31 tesA BXF_0027 BX_875 1)pBMT-3_ccdAB_PT7- 33 tesA_PT7-nphT7-hbd-crt- ter BXF_0028 BX_878 1)pBMT-3ccdAB-T7- 33 tesA- PT7_nphT7_hbd_crt_ter BXF_0028 BX_878 1)pBMT-3_ccdAB_PT7- 33 tesA_PT7-nphT7-hbd-crt- ter BXF_0029 BX_879 1)pBMT-3_ccdAB_PT7- 33 tesA_PT7-nphT7-hbd-crt- ter BXF_0030 BX_881 1)pBMT-3_ccdAB_PT7- 33 tesA_PT7-nphT7-hbd-crt- ter BXF_0031 BX_864 1)pBMT-3_ccdAB_PT7- 33 tesA_PT7-nphT7-hbd-crt- ter 2)pET-28b(empty vector) BXF_0033 BX_878 1)pBMT-3_ccdAB_PT7- 32 nphT7-hbd-crt-ter BXF_0034 BX_879 2)pBMT-3_ccdAB_PT7- 32 nphT7-hbd-crt-ter

(90) A base strain was constructed by chromosomal integration of Hbd and Crt into the BX_1018 parent strain. The following set of strains were transformed and evaluated in small scale for both FAME production and metabolite accumulation.

(91) TABLE-US-00006 TABLE 4b list of strains used for testing hbd and crt presence in FAME production Strain Parent(s) Plasmid 1 Plasmid 2 BXE_062 BX_1018 pET-PpstsIH-Aagr pACYC-PpstsIH-nphT7(SV)-ter- PpstsIH-fadB-Maqu BXE_207 BX_1018 pET-PpstsIH-Aagr pACYC-PpstsIH-nphT7(SV)-ter- PpstsIH-fadB-PphoE-Maqu BXE_229 BX_1018 pET-PpstsIH-Aagr pACYC-PpstsIH-nphT7(SV)-ter- yibD:PyibD-hbd-crt PpstsIH-fadB-PphoE-Maqu BXE_230 BX_1018 pET-PpstsIH-Aagr pACYC-PpstsIH-nphT7(SV)-ter- yibD:PyibD-hbd-crt PpstsIH-fadB-Maqu

(92) To better understand the impact of Hbd/Crt expression, metabolite accumulation was monitored in cell lysate following incubation with malonyl-CoA and acetyl-CoA substrates. The results of this assay, as presented in FIG. 12, showed increased accumulation of C4-C6-CoA intermediates consistent with the expected activity on keto- and hydroxy-C4-CoAs.

(93) Engineering -Keto Acyl-CoA Synthases (FabH)

(94) A screening approach was employed for -keto acyl-CoA synthase homologs to identify candidates for lauric acid production based on demonstrated activity on C4- to C10 acyl-CoA substrates. Greater than 70 homologs have been synthesized, expressed, purified and evaluated for activity in vitro.

(95) Synthase candidates identified to have significant activity on C4- to C10-CoA substrates were incorporated into production hosts and evaluated for FFA production in shake flask. FIG. 1 shows FFA production profiles at 68 hours for several of the engineered strains (Table 4c) exhibiting significant lauric acid production. As shown, both lauric acid and total FFA production profiles are modulated by the individual synthase candidate(s) incorporated. For example, strain BXF_198, which contains the Aagr fabH construct, shows the highest specificity for lauric acid, whereas co-expression of Rsol fabH corresponds to the highest titer in total FFA. All four synthase combinations shown in FIG. 1 have been selected for Example 3 focused on production of methyl laurate.

(96) TABLE-US-00007 TABLE 4c Bacterial strains with specific plasmids used in the screening phase Strain Host Plasmid 1 Plasmid 2 BXF_166 BX_978 1009_pACYC-PpstsIH- 1007_pET28b- nphT7(I147S,F217V)-ter- lacI-PpstsIH-Madh TT_PpstsIH-fadB fabH-Aagr fab H BXF_169 BX_985 1009_pACYC-PpstsIH- 1008_pET28b- nphT7(I147S,F217V)-ter- lacI-PpstsIH-Anip TT_PpstsIH-fadB fabH-Aagr fab H BXF_185 BX_985 1009_pACYC-PpstsIH- 1045_pET28b- nphT7(I147S,F217V)-ter- lacI-PpstsIH-Rsol TT_PpstsIH-fadB fabH-Aagr fab H BXF_198 BX_985 1009_pACYC-PpstsIH- 1123_pET28b- nphT7(I147S,F217V)-ter- lacI-PpstsIH-Aagr TT_PpstsIH-fadB fab H
Baseline FFA Analysis

(97) A more comprehensive baseline analysis was completed with a subset of FFA production strains with various synthase combinations as described above. Data for strain BXF_169 is presented; similar trends were observed among all strains that were evaluated in the more comprehensive tests. The data presented in FIG. 2 shows a time course of lauric acid production for strain BXF_169. In the shake flask test conditions, the strain exhibited a stable initial production rate for 10-20 hours. After the 20 hours, the rate decreased significantly and product titer levels off.

(98) For all strains analyzed, samples were taken at each time point and analyzed for transcript, expression, and activity for key enzymes in the fatty acid production pathway. FIGS. 3 and 4 show the relative mRNA expression of the pathway genes and the corresponding enzyme activity over time for BXF_169. Transcription levels were good, but also differed between the five genes despite being driven from the same promoter. Both transcript and enzyme activity showed a decreasing trend over time, with enzyme activities dropping for several reactions at the 24 hour time point. Similar trends were observed for all other FFA production strains evaluated.

(99) In addition to reduced mRNA and enzyme activity, the 24-hour time point was also characterized by increased insoluble protein accumulation and decreased glucose consumption for all strains (data not shown). As fatty acids including lauric acid are known to accumulate inside the cells in the absence of specific transporters, it was hypothesized that the reduction in productivity at 24 hours is due to intracellular FFA toxicity.

(100) In Vitro Analysis of the Fatty Acid Synthesis Pathway

(101) An assay was developed by reconstructing the fatty acyl-CoA pathway in vitro with purified enzymes. The in vitro reconstruction simplified identification of rate-limiting steps, which were characterized by metabolite accumulation under reaction conditions. There were several benefits of in vitro pathway reconstitution including isolation of pathway flux from competitive enzymes (e.g. thioesterases), substrate limitations (e.g. NADH pools), and balanced expression of multiple pathway enzymes. The equilibrium of the pathway was evaluated by quantifying all 20 pathway intermediates from malonyl-CoA to lauroyl-CoA in the presence of varying amounts of enzymes or substrates (acyl-CoA intermediates).

(102) FIG. 5 shows the accumulation of pathway intermediates for the C4 to C6 elongation cycle observed while varying the enzymes for the keto acyl-CoA reductase (KCR) and 3-hydroxyacyl-CoA dehydratase (3HCDh) reactions. As shown, when the pathway was reconstructed with FadB, there was significant accumulation of 3-hydroxybutyryl-CoA, suggesting insufficient 3HCDh activity to drive the reaction forward. The observed accumulation may be due to the preference for this enzyme to catalyze the reverse reaction, which may also be reducing overall forward pathway flux in vivo. However, when FadB is supplemented with Hbd and/or Crt (alternative KCR and 3HCDh enzymes that have significant activity in the forward direction with C4 intermediates), a reduction in 3-hydroxybutyryl-CoA accumulation was observed. These data suggested that the supplemental activity was sufficient to drive the pathway forward to butyryl-CoA and that integration of Hbd and Crt into production hosts may enhance production of longer chain fatty acids.

(103) Synthase Mutant Evaluations

(104) FabH variants were isolated from a 96-well plate-based screen developed to detect beneficial mutations with improved activity on C10-CoA. Following the initial screen of >1000 mutants, positive variants were sequenced and activity on C6-C10-CoA was evaluated. As shown in FIG. 13, three of the purified variants identified were confirmed to have increased activity on C6-C10-CoA substrates.

(105) Following positive confirmation, FabH mutants were evaluated in vivo. The following strains were constructed by incorporating the FabH mutations into BXE_198 and BXE_233.

(106) Strains were evaluated in the standard 1 mL screening protocol for FAME production in 20 hours (FIG. 14). As shown below, increased methyl laurate observed with the E37K (strain BXE_271) and D196G/K342E (strains BXE_273 and BXE_243) variants compared with the control strains (strains BXE_198 and BXE_233). However, as with the hbd/crt module, it is expected that these mutations may have a greater impact in production strains with improved WES activity.

(107) It has been consistently demonstrated with current production strains that the required expression of Aagr FabH to achieve target activities in lysate requires a significant fraction of the total protein pool. Furthermore, even with a high level of expression, the FabH activity on C10-CoA is often times at or slightly below the target activity.

(108) TABLE-US-00008 TABLE 4d The following strains were constructed by incorporating the FabH mutations into BXE_198 and BXE_233. Strain Parent(s) Plasmid 1 Plasmid 2 BXE_198 BX_1018 pET-PpstsIH-Aagr-TS Maqu pACYC_PpstsIH nphT7(SV)-ter- PpstsIH-fadB BXE_233 BX_1018 pET_PpstsIH-Aagr-PtpiA- pACYC-PpstsIH-nphT7(SV)-ter- accDA_PrpiA-accB-accC PpstsIH-fadB-PphoE-Mhyd BXE_271 BX_1018 pET_PpstsIH-Aagr(E37K)- pACYC_PpstsIH nphT7(SV)-ter- PTS-Maqu PpstsIH-fadB BXE_272 BX_1018 pET_PpstsIH-Aagr(E51G, pACYC_PpstsIH nphT7(SV)-ter- S357G)-PTS-Maqu PpstsIH-fadB BXE_273 BX_1018 pET_PpstsIH-Aagr(D196G, pACYC_PpstsIH nphT7(SV)-ter- E342E)-PTS-Maqu PpstsIH-fadB BXE_243 BX_1018 pET_PpstsIH-Aagr(D196G, pACYC_PpstsIH nphT7(SV)-ter- K342E)-Ptpi-accDA_PrpiA- PpstsIH-fadB-PphoE-Mhyd accB-accC BXE_244 BX_1018 pET_PpstsIH-Aagr(D196G, pACYC_PpstsIH nphT7(SV)-ter- Q219R)-PtpiA-accDA_PrpiA- PpstsIH-fadB-PphoE-Mhyd accB-accC

Example 2

(109) Optimization of Wax Ester Synthase (WES) Activity for Methyl Laurate Production

(110) WES candidates were expressed, purified, and evaluated for solubility and FAME production in vitro. Based on the results of the initial screen, 21 WES candidates were chosen for further evaluation including substrate specificity and in vivo FAME production. In vitro assays were completed by measuring product formation following the addition of individual CoA substrates. As summarized in FIG. 6, a range of activities was observed on the various substrates and a number of candidates were identified based on high overall activity (Svar, Maqu) or specificity for substrates C12-CoA (M360.2, Acip). The sequences of the WES used are provided in Table 1 above.

(111) As an orthogonal method for testing in vivo activity, nine of the WES candidates (Table 4f) shown to be active on lauroyl-CoA in the presence of methanol were expressed in a fatty acid production host.

(112) TABLE-US-00009 TABLE 4f Nine WES candidates shown to be active on lauroyl-CoA in the presence of methanol were expressed in a fatty acid production host Strain Host Plasmid 1 Plasmid 2 BXE_003 BX_926 583_pET28b-lacI- 1005_pACYC-PpstsIH- PpstsIH-fadBA nphT7-ter-TT_PpstsIH- Abor BXE_013 BX_926 583_pET28b-lacI- 1071_pACYC-PpstsIH- PpstsIH-fadBA nphT7-ter-PpstsIH- Gpro BXE_016 BX_926 583_pET28b-lacI- 1076_pACYC-PpstsIH- PpstsIH-fadBA nphT7-ter-PpstsIH- Requ BXE_017 BX_926 583_pET28b-lacI- 1077_pACYC-PpstsIH- PpstsIH-fadBA nphT7-ter-PpstsIH- LMED BXE_018 BX_926 583_pET28b-lacI- 1078_pACYC-PpstsIH- PpstsIH-fadBA nphT7-ter-PpstsIH- Aazu BXE_019 BX_926 583_pET28b-lacI- 1079_pACYC-PpstsIH- PpstsIH-fadBA nphT7-ter-PpstsIH- Msme BXE_020 BX_926 583_pET28b-lacI- 1080_pACYC-PpstsIH- PpstsIH-fadBA nphT7-ter-PpstsIH- Ajun BXE_021 BX_926 583_pET28b-lacI- 1081_pACYC-PpstsIH- PpstsIH-fadBA nphT7-ter-PpstsIH- M360.2 BXE_022 BX_926 583_pET28b-lacI- 1082_pACYC-PpstsIH- PpstsIH-fadBA nphT7-ter-PpstsIH- ACIP

(113) Small-scale evaluations were completed for each strain cultured at OD.sub.600=2.0 in a 20 mL capped glass test tube with a working volume of 2 mL. Samples were taken at 24 hours by removing 1 mL of the culture for growth and glucose measurement and extracting the remaining broth with MTBE prior to analyzing for FAME production by GC-MS. As shown in FIG. 7, methyl laurate titers ranging from 0.04-0.5 g/L were observed, indicating modest in vivo WES activity.

(114) Specificity of product formation observed in vivo was significantly different than what would be predicted based upon the in vitro assays. This discrepancy may have been due to the production profile of the thiolase FFA strains, which produced nearly equivalent titers from C6 to C16 FFA. Due to the limitations of screening the wax ester synthase candidates in the thiolase strain, subsequent in vivo characterization was performed in synthase-based strains, which produced C12 FFA and FAME products at higher specificity, rate and titer.

(115) WES High-Throughput Screening

(116) A 96-well plate, Nile red-based assay has been developed for high-throughput quantification of FAME production by fluorescence. Mutant libraries were constructed with Maqu WES. The top 20 mutants identified in the screen have been isolated, sequenced, cloned into production hosts and evaluated for FAME and FFA production in the 1 mL method. While comprehensive data analysis for the 1 mL confirmations is pending, initial results showed significantly improved FAME production with at least two WES constructs identified by this method. As demonstrated in FIG. 17, both mutations resulted in improved methyl laurate production when compared with the control strain, while maintaining a high degree of specificity.

(117) Similarly, mutants of Mhyd were made and the methyl laurate production determined. The results are shown in FIG. 16.

Example 3

(118) Construction and Evaluation of Methyl Laurate Producing Strains

(119) Engineering of Strains for Methyl Laurate Production

(120) Numerous methyl laurate production strains have been constructed, incorporating key pathway modules developed in Examples 1 and 2 above and building upon the malonyl-CoA production technology as described in WO2014026162A1 (OPX Biotechnologies Inc., USA). Small-scale evaluations were completed for each strain cultured at OD.sub.600=2.0 in a 20 mL capped glass test tube with a working volume of 1 mL. Samples were taken at 24 hours by extracting the entire culture with MTBE and analyzing for FAME production by GC-MS. This 1 mL protocol was instituted in an effort to reduce volatile loss of FAME products seen during shake flask evaluations.

(121) TABLE-US-00010 TABLE 5 methyl laurate production strains used in Example 3 Strain Base strain Plasmid 1 Plasmid 2 BXE_233 BX_1018 pET_PpstsIH-Aagr-PtpiA- pACYC-PpstsIH-nphT7(SV)-ter- accDA-PrpiA-accB-accC PpstsIH-fadB-PphoE-Mhyd BXE_275 BX_1018 pET_PpstsIH-Aagr-PtpiA- pACYC-PpstsIH-nphT7(SV)-ter- accDA-PrpiA-accB-accC PpstsIH-fadB-PphoE-Aazu BXE_276 BX_1018 pET_PpstsIH-Aagr-PtpiA- pACYC-PpstsIH-nphT7(SV)-ter- accDA-PrpiA-accB-accC PpstsIH-fadB-PphoE-Hche BXE_279 BX_1018 pET_PpstsIH-Aagr-PtpiA- pACYC-PpstsIH-nphT7(SV)-ter- accDA-PrpiA-accB-accC PpstsIH-fadB-PphoE-Maqu

(122) In FIG. 8, 24 hour FAME production data is shown for 50 of the >100 methyl laurate producing strains screened in the 1 ml assay since the May SCM. In this strain set, titers >1 g/L have been obtained in 20 hours of production with biomass levels 1 gDCW/L. Furthermore, specificities between 70-98% on a FAME basis have been observed.

(123) FIG. 15 shows the 1 mL screening results for strains expressing four WES candidates shown in Table 5. These results show that varying the WES leads to significant changes in methyl laurate production. Furthermore, Hche showed high levels of production. FIG. 18 also shows that while the majority of the activities (FabH, FadB, Ter) were not significantly different between the two hosts, BXE_233 and BXE_062, the WES activity was nearly three-fold higher in BXE_233 when compared with BXE_062. The significant differences in methyl laurate production seen with differing WES candidates, and with different expression constructs for the same WES enzyme, support the hypotheses that WES activity remains limiting in current production strains.

Example 4

(124) Fermentation Method Development and Optimization for Methyl Laurate Production

(125) Initial Development of a 1 L Bioprocess for Methyl Laurate Production

(126) Development of a 1 L bioprocess for methyl laurate was carried out to support evaluation of production strains under pH-controlled conditions and at biomass concentrations more representative of commercial production.

(127) Several process parameters (Table 6) were explored, including pH setpoint, methanol feeding, temperature profile and incorporation of a second phase for increased FAME recovery.

(128) A subset of the data generated is shown in FIG. 9. Overall, the methanol feeding and control strategy did not appear to have a significant impact on methyl laurate production or overall fermentation performance. The inclusion of a second phase appeared to be a slight, positive effect on FAME recovery. The incorporation of the 35 C. to 37 C. temperature shift profile showed a positive effect on production, Based on these results, the following baseline process as shown in Table 7 was established and utilized for the subsequent 1 L fermentations and evaluations of methyl laurate producing strains engineered in Example 3.

(129) TABLE-US-00011 TABLE 6 Several process parameters used in Example 4 Production Methanol Feed 2.sup.nd Temperature Production Condition Profile Phase Profile pH Medium Control 1% (v/v) MeOH N/A 37 C. 7.4 FM12 + 9 mM added at TS; bolus phosphate additions every 8-12 hours to maintain 1% MeC14 1% (v/v) MeOH 50 g/L 37 C. 7.4 FM12 + 9 mM FAME added at TS; bolus C14 phosphate additions every 8-12 FAME hours to maintain 1% 35 C. to 1% (v/v) MeOH N/A 35 C. .fwdarw.37 C. 7.4 FM12 + 9 mM 37 C. added at TS; bolus phosphate additions every 8-12 hours to maintain 1% MeOH 0.5% (v/v) MeOH N/A 37 C. 7.4 FM12 + 9 mM Feed added at TS; bolus phosphate additions every 8-12 hours to maintain 0.5% pH 7 1% (v/v) MeOH N/A 37 C. 7.4 FM12 + 9 mM added at TS; bolus phosphate additions every 8-12 hours to maintain 1%

(130) TABLE-US-00012 TABLE 7 Baseline process used in fermentation of methyl laurate producing strains engineered in Example 3 Production Methanol Feed Temperature Production Condition Profile 2.sup.nd Phase Profile pH Medium Baseline 1% (v/v) MeOH 50 g/L C14 35 C. .fwdarw.37 C. 7 FM12 + Process added at TS; FAME 9 mM bolus additions at phosphate every 8-12 hours to maintain 1%

(131) BXE_276 strain was tested as mentioned above. The average production time course for the triplicate BXE_276 was run. Fairly constant methyl laurate production rates were observed over 36.5 hours with an average titer of 3 g/L methyl laurate. Interestingly, this strain produced a significant amount of methyl decanoate (3-5 g/L), resulting in significantly higher total FAME production than observed with previous strains (FIG. 19). BXE_276 showed higher specificity for production of methyl decanoate than methyl laurate in 1 L, which is in contrast to the higher specificity demonstrated in 1 mL for methyl laurate production (69%).

REFERENCES

(132) Heath et al., Prog. Lipid Res. 40(6):467-97 (2001) McCue et al., Nucleic Acids Res., 29(3):774-82 (2001) Zhang et al., J. Biol. Chem. 277 (18):15558-65 (2002) Chang et al., J. Bacteriol. 154(2):756-62 (1983) Abdel-Ahmid et al., Microbiol. 147(6):2001 Mat-Jan et al., J. Bacteriol. 171(1):342-8 Bunch et al., Microbiol. 143(1):187-95 (1997) Enoyl-Acyl Carrier Protein (fabI) Plays a Determinant Role in Completing Cycles of Fatty Acid Elongation in Escherichia coli, Richard J. Heath and Charles 0. Rock, J. Biol. Chem. 270:44, pp. 26538-26543 (1995), Beguin, P and Aubert, J-P (1994) FEMS Microbial. Rev. 13: 25-58 Ohima, K. et al. (1997) Biotechnol. Genet. Eng. Rev. 14: 365414. Antonenkov, V., D. et al. Van Veldhoven, P., P., Waelkens, E., and Mannaerts, G. P. J. Biol. Chem. 1997, 272:26023-26031. Reed, 1981 Arthur Lesk (2008), Introduction to bioinformatics, 3.sup.rd edition, Thompson et al., Nucleic Acids Research 22, 4637-4680, 1994, Katoh et al., Genome Information, 16(1), 22-33, 2005.

(133) U.S. provisional patent application No. 62/044,621 filed Sep. 2, 2015, is incorporated herein by reference.

(134) Numerous modifications and variations on the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.